There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations ...

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...

Experts discuss the relationship between obesity and heart failure while referencing new clinical trial results.

Subsequently, AI has become an important tool to overcome challenges and support the development of personalised care. One ...

The European Commission (EC) has authorised GSK’s Arexvy for active immunisation against LRTD caused by RSV in adults aged 50 ...

The FDA has granted ODD status to Nuvectis Pharma’s NXP800 for ARID1a-deficient ovarian, fallopian tube and primary ...

The FDA cited concerns with the API manufacturing plant including falsifying production records and failing to follow proper ...

If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic ...

The French government funds will support clinical development for T cell-activating monoclonal antibody and another project.

GlobalData tracks 44 drugs in development for Chagas Disease (American Trypanosomiasis) by 32 companies/universities/institutes. The top development phase for Chagas Disease (American Trypanosomiasis) ...

GlobalData tracks 43 drugs in development for Vitiligo by 40 companies/universities/institutes. The top development phase for Vitiligo is preclinical, with 14 drugs in that stage.

GlobalData tracks 16 drugs in development for Goiter by 16 companies/universities/institutes. The top development phase for Goiter is preclinical, with eight drugs in that stage.